CPC-111 small molecule stimulator of oxygen metabolism to generate adenosine triphosphate data

CYPR announced that data from the latest 30 patients treated in an ongoing double-blind, placebo-controlled Phase II trial show a cardioprotective effect of CPC-111, with more than a 30 percent reduction in CKMB, an enzyme marker of heart cell death. Other parameters of heart function also showed statistically significant improvement by the drug in the post-surgical period. These include cardiac output, left ventricular stroke work index, and cardiac index.

The results also show that patients receiving the agent require 50 percent less inotropic measures (to support heartbeat) in the intensive care unit, and are discharged from the ICU sooner. ...